未登录.png)
分享.png)
收藏分享 收藏 Muscle strength trajectories and outcomes in critically ill patients: A prospective multicentre cohort study危重患者肌肉力量轨迹与结局：一项前瞻性多中心队列研究
Wu, Ting-Ting; Lin, Xiu-Xia; Chen, Gao-Yan; Yao, Jun; Xiong, Jing; Luo, Chen-Juan; Zhuang, Yao-Ning; Xu, Mei-Lian; Chen, Xue-Xian; Chen, Mei-Rong; Li, Hong 分享 收藏 Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study伊帕罗利单抗和图沃纳利单抗（QL1706）联合化疗和贝伐珠单抗，用于表皮生长因子受体抑制剂（EGFRi）耐药、EGFR突变、晚期非小细胞肺癌（NSCLC）：DUBHE-L-201研究中Cohort 5的更新结果Fang, W. F.; Yang, Y.; Zhao, Y.; Huang, Y.; Zhao, H.; Zhou, N.; Zhang, Y.; Chen, L.; Zhou, T.; Chen, G.; Li, H.; Wu, T.; Xue, S.; Kang, X.; Zhang, L. 分享 收藏 分享 收藏 分享 收藏 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)Cheng, Y.; Liu, Y.; Zhang, W.; Wu, L.; Zhou, C.; Wang, D.; Xia, B.; Bi, M.; Fu, X.; Li, C.; Chen, G.; Lv, D.; Zhao, Y.; Huang, J.; Li, M.; Yi, T.; Huang, X.; Yang, R.; Chen, Z.; Wang, Y. 分享 收藏 Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term resultsLu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J. 分享 收藏 Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 studyYang, Y.; Wang, Z.; Fang, J.; Yu, Q.; Han, B.; Cang, S.; Chen, G.; Mei, X.; Yang, Z.; Stefaniak, V.; Lin, Y.; Wang, S.; Zhang, W.; Sun, L.; Zhang, Y. 分享 收藏 First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trialZhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z. 分享 收藏 分享 收藏 Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S. 分享 收藏 Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancerZhou, C.; Gao, G.; Wu, L.; Wang, Z.; Chen, G.; Huang, D.; Yang, Z.; Zhou, C.; Liu, L.; Li, H. Y. 分享 收藏 Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)Fang, J.; Zhao, Y.; Han, B.; Chen, G.; Yang, Z.; Bi, M.; Zhang, L.; Molife, C.; Zhao, Y.; Zhang, L. 分享 收藏 分享 收藏 A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancerAi, X.; Pan, Y.; Shi, J.; Yang, N.; Liu, C.; Zhou, J.; Zhang, X.; Dong, X.; He, J.; Li, X.; Chen, G.; Li, X.; Zhang, H.; Liao, W.; Zhang, Y.; Ma, Z.; Zhang, B.; Zhang, D.; Lu, S. 分享 收藏 Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%Wu, Y-L.; Zhang, L.; Fan, Y.; Zhou, J.; Zhang, L.; Zhou, Q.; Li, W.; Hu, C.; Chen, G.; Zhang, X.; Zhou, C.; Souza, F.; Lin, J.; Wang, J.; Li, B.; Mok, T. 分享 收藏 Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202)Liu, Y.; Cheng, Y.; Wang, Q.; Li, K.; Shi, J.; Wu, L.; Han, B.; Chen, G.; He, J.; Wang, J.; Qin, H.; Li, X. 分享 收藏 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)Yang, Y.; Sun, J.; Wang, Z.; Fang, J.; Yu, Q.; Han, B.; Cang, S.; Chen, G.; Mei, X.; Yang, Z.; Ma, R.; Bi, M.; Ren, X.; Zhou, J.; Li, B.; Zhou, H.; Wang, S.; Xu, W.; Peng, B.; Zhang, L. 分享 收藏 Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202)Cheng, Y.; Wang, Q.; Li, K.; Shi, J.; Wu, L.; Han, B.; Chen, G.; He, J.; Wang, J.; Qin, H.; Li, X. 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
